The trial marks the first time the technology, conformal FLASH proton therapy, is being tested in humans. The hope, ultimately, is to preserve quality of life in patients by reducing side effects.

Researchers at Peter Mac have discovered why breast cancer treatment stops working for some patients, uncovering the unexpected role of one of the body's most important cancer-fighting proteins.

Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on the horizon.

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

Q&A with Steven Corsello, MD, on a new approach to treating pancreatic cancer.

Exciting new work from K. Christopher Garcia, co-investigator on MATCHMAKERS 👏   The study published in Nature Biotechnology shows that deep peptide-recognition profiling, combined with machine learni...

Opposing oncogenic and tumor-suppressive forces establish a progenitor-like state that builds a self-reinforcing niche to drive benign-to-malignant transition in pancreatic cancer models. Disruption o...

DNA-sequencing data from primary tumours and paired metastases from participants in the TRACERx lung study and PEACE autopsy programme are used to analyse the metastatic diversity of advanced non-smal...

Each year, the American Association for Cancer Research (AACR) convenes researchers at the leading edge of oncology at its Annual Meeting. This year, the Mark Foundation for Cancer Research is proud…

NMDAR expression is sufficient to induce B cell recruitment and affinity maturation, resulting in receptor-modulating antibodies that connect anti-cancer immunity and autoimmunity.

NEW YORK, NY – March 25, 2026 – The Mark Foundation for Cancer Research today announced a major evolution of its flagship Emerging Leader Award (ELA) program, significantly increasing its financial…

New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early...

New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early...

Institutes and private organizations like the Mark Foundation are promising to spend more on cancer research to counteract a decline in federal dollars.

We are pleased to announce that Daniel Kirschenbaum has been selected as the recipient of the 2026 EACR-Mark Foundation-Pezcoller Foundation Rising Star Award. Established in 2023, this prestigious aw...

By the European Association for Cancer Research We are pleased to announce that Daniel Kirschenbaum has been selected as the recipient of the 2026 EACR-Mark Foundation-Pezcoller Foundation Rising Star...

The research looked at the genes which can cause cancer, with a focus on the bowel and liver